

Disclosures


 Has no affiliations with commercial interests to disclose

Objectives of the Talk


- To learn about AML and subtypes
- To review current and emerging treatments
- To discuss managing side-effects from the AML and treatment
- To review the importance of communicating with your team

Etiology of AML


- A disease derived from a new, single, genetically aberrant cell
- Family factors some families have increased susceptibility to accumulate genetic injury during life
- Environment medications, harmful chemicals, radiation, chemotherapy can cause problems
- Time (age) allows accumulation of events




Mutations Accumulate and Get Fixed (Mostly When We're Young)













Mutations May Occur in Critical Areas of Our Genes













18

Major Subtypes of AML

World Health Organization


- Acute myeloid leukemia with specific genetic abnormalities
 - AML with t(8;21)
 - AML with inv(16)
 - APL with t(15;17)
- AML associated with myelodysplastic syndrome
- AML associated with previous chemo or radiotherapy
- AML (not otherwise specified)
 - Subtypes based on appearance under the microscope

Vardiman, et. al. Blood. 2009;114:937-951

Risk Stratification Molecular **Risk Status Cytogenetics Abnormalities** Normal cytogenetics: Favorable Risk Inv(16) or t(16;16) or t(8;21) NPM1 mutation (without FLT3-ITD) or CEBPA mutation Intermediate Risk Normal Cytogenetics Inv(16) or t(16;16) or C-kit mutation t(8;21) +8 or t(9;11) Poor Risk 3 or more abnormalities Normal cytogenetics: FLT3-ITD mutation Monosomal karyotype Abnormal 5 or 7 11q23 or inv(3) or t(3;3) or t(6;9) or t(9;22) NCCN Guidelines Version 1.2015





- Acute Promyelocytic Leukemia t(15;17)
 - Very different than other types of AML
 - Excellent prognosis with unique treatment
- AML that is reliably cured with chemotherapy (*"core binding factor AML"*)
 t(8;21), inv(16), t(16;16), NPM1 mutation
- AML *not* reliably cured with chemotherapy
 - Most of the other forms of AML





Everyone Starts With Chemotherapy


- Starts with "Induction" aka "3+7"
 - Goal: to achieve a complete remission
 - 3 days of idarubicin/daunorubicin
 - 7 days of cytarabine
- Check the bone marrow around 10 -14 days later
- Then wait for blood count recovery
































Supporting Patients Through Treatment

- Maintain blood counts
 - Red cell and platelet transfusions
 - We can't give white cells reliably
- Treat/Prevent infections
 - Antibacterial, antiviral, antifungal agents important
- Control bleeding problems
- · Control nausea, diarrhea

34

36

What Can Patients Do To Stay Healthy?

- Stay in the loop!
 - Ask questions, know the plan, keep your family around for important conversations.
- Wash your hands!
 - Soap and water the best in the hospital, the gel is second best.
 - Always wash after the bathroom, before eating and after walking out of the room.

What Can Patients Do To stay Healthy?

- Keep moving!
 - Walking and moving can be hard but SO important to help maintain strength.
 - Ask to speak to a physical therapist.
 - Wear a mask in the hospital.
- Keep eating!
 - If eating is tough, ask to speak to a nutrition specialist.
 - Eat safe food: fresh, washed, or cooked. Plant-based diets are generally healthy diets.

What Can Patients Do To Stay Healthy?

- Keep your social contacts!
 - · But avoid crowds in small spaces
 - · Let friends/family help
- Discuss your mood!
 - It is normal to be depressed at times BUT
 - · Depression can be an impediment to healing
- Protect your time and space!
 - · Getting better is a full time job
 - Keep a perspective on work

